Category: Blog

Featured

Lights, Camera, Action on AI-Powered Drug Discovery

Docuthon is the world’s first documentary-creating competition on AI-powered drug discovery, providing an opportunity for every talented filmmaker to get involved in a cutting-edge industry, share a terrific science story, and inspire the next generation of scientists in longevity.

Read More »
Featured

Announcing the Biomarkers of Aging Consortium

A significant and vital step forward for the longevity field: the Biomarkers of Aging Consortium. Formed of a diverse group of academic and industry members, the Consortium seeks to “establish reliable biomarkers of aging, particularly for the identification and evaluation of longevity interventions. Learn more…

Read More »
Featured

Action at the Governmental Level for Longevity

As partners of the Alliance for Longevity Initiatives (A4LI), SRF is excited to announce the formation of the Longevity Science Caucus to promote initiatives aimed at increasing the healthy average lifespan of all Americans. Read more…

Read More »
Latest News

Scenes from the Lab

Much of SRF’s research would not be possible without complex scientific equipment. SRF would like to thank its donors for their generous contributions which allow for the purchasing of this equipment, directly enabling research in ending age-related diseases.

Read More »

SENSible Question: How Might Cyclarity’s UDP-003 Compare to EDTA Chelation?

A supporter asks us to compare the expected benefits of Cyclarity’s UDP-003 to chelation therapy. Although both target the age-related scourge of atherosclerotic cardiovascular disease (ASCVD), EDTA (if it works) dampens down the worst aspects of having ASCVD, while UPD-003 is a SENS “damage-repair” therapeutic which is expected to remove the underlying damage itself and reverse the disease process.

Read More »

The Iron Fist Unleashed!

One way senescent cells accumulate is when one senescent cell turns a neighboring cell senescent through SASP secretion. SRF scientists have discovered that these secondary senescent cells are resistant to the classic senolytic drugs. However, they have identified a new senolytic strategy that kills these senescent cells.

Read More »

A TAME Attempt to Slow Aging Part 5: Winning the Game with a Weak Hand

Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In the final installment of this 5-part series, we look at TAME itself: how it’s structured, how it’s justified, and how the results could impact the push for longevity therapeutics.

Read More »

SENSible Question: New MitoSENS Strategies

A supporter asks us to elaborate on projects other than allotopic expression (AE), that SRF has undertaken that are targeting mitochondrial dysfunction; and how they relate to the original strategy of allotopic expression?

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: